What other option is available for treating newly diagnosed multiple myeloma in patients not intended to receive a stem cell transplant? The other option [for these patients] is dara-Rd [daratumumab (Darzalex), lenalidomide, and dexamethasone] supported by the MAIA study, looking at dara...
CyBorD is another commonly used immunomodulatory drug-sparing regimen for MM. We evaluated the safety and efficacy of dara-CyBorD and administered the first dara infusion as a split dose over 2 days in pts with NDMM or relapsed MM (RMM) after 1 prior line of therapy. Methods: This is ...
CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance Front Immunol, 9 (2018), p. 2134 View in ScopusGoogle Scholar 33 R Abu Eid, GS Razavi, M Mkrtichyan, J Janik, SN Khleif Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repu...
TPS8051 Background: Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that leverages aminopeptidases and rapidly releases alkylating agents inside tumor cells. Melflufen + dex showed clinical efficacy and was well tolerated in pts with heavily pretreated RRMM (HORIZON...
We report updated results with additional pts and longer follow-up.Methods:Pts had MM, ≥3 prior lines of therapy (LOT; including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or were double refractory to a PI and IMiD, and had not received anti-CD38 therapy in ≤90 d....
Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late‐stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five‐drug combination pomalidomide, bortezomib, doxorubicin, dexamethasone, and ...
Four pts died on study due to sudden death, COVID-19 pneumonia, septic shock, & COVID-19 (none were considered study drug-related). These IA data suggest IDd has a positive risk-benefit profile in RRMM pts, with a ≥VGPR rate of 30.5%, median PFS of 17.0 m, & a low rate of ...